Tag Archives: Dermatology

OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients. Pasadena, CA, U.S.A., 5-Jul-2019 — /EuropaWire/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), … Read the full press release

Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany

The interregional professional association for nuclear medicine in Hanau is the first treatment center in Germany offering Rhenium-SCT® for the treatment of non-melanoma skin cancer GARCHING N. MUNICH, Germany, 13-May-2019 — /EuropaWire/ — OncoBeta® GmbH, a commercial stage Medical Device … Read the full press release

New Study Reconfirms Effectiveness and Safety of Fotona Dynamis Laser Treatment for Minimally-Invasive Urinary Incontinence

LJUBLJANA, Slovenia, 21-Sep-2018 — /EuropaWire/ — The latest study published in the World Journal of Urology (Comparison between erbium‑doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence – https://doi.org/10.1007/s00345-018-2445-x) provides further … Read the full press release

Sandoz: EMA Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for marketing authorization of infliximab

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab … Read the full press release

Novartis’s omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with severe form of chronic skin disease CSU

Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four … Read the full press release